WEIGANG REN^1,#, JING LI^2,#, RUIJIANG ZENG^3,4, LIANG ZHU^3,4,*

BIOCELL, Vol.48, No.9, pp. 1323-1330, 2024, DOI:10.32604/biocell.2024.051747 - 04 September 2024

Abstract Background: Clear cell renal cell carcinoma (ccRCC) stands as the most prevalent form of kidney cancer, accounting for a significant proportion of malignancies affecting the kidneys. ccRCC is well known as a type of tumour with immunogenicity. Immune checkpoint inhibitors (ICIs) aim to enhance the anticancer immune response in ccRCC by blocking programmed cell death 1 ligand 1/programmed death 1 (PD-L1/PD-1) pathways. In a previous study, we showed that RING finger protein 26 (RNF26) degrades chromobox 7 (CBX7) to activate the tumor necrosis factor (TNF) in ccRCC. Methods: We analyzed The Cancer Genome Atlas (TCGA)… More > Graphic Abstract

HAIQING HU^1,#,*, HAO YANG^2,#, SHUAISHUAI FAN³, XUE JIA³, YING ZHAO³, HONGRUI LI³

Oncology Research, Vol.32, No.8, pp. 1335-1346, 2024, DOI:10.32604/or.2024.044174 - 17 July 2024

Abstract Long non-coding RNAs (lncRNAs) have been implicated in cancer progression and drug resistance development. Moreover, there is evidence that lncRNA HOX transcript antisense intergenic RNA (HOTAIR) is involved in colorectal cancer (CRC) progression. The present study aimed to examine the functional role of lncRNA HOTAIR in conferring radiotherapy resistance in CRC cells, as well as the underlying mechanism. The relative expression levels of HOTAIR were examined in 70 pairs of CRC tumor and para-cancerous tissues, as well as in radiosensitive and radioresistant samples. The correlations between HOTAIR expression levels and clinical features of patients with… More >

KAIWEN TIAN^#, HANZHONG CHEN^#, QIANQIAN WANG, FENGLIAN JIANG, CHUNXIANG FENG, TENG LI, XIAOYONG PU, YANLIN TANG^*, JIUMIN LIU^*

BIOCELL, Vol.48, No.5, pp. 817-834, 2024, DOI:10.32604/biocell.2024.048737 - 06 May 2024

Abstract Background: The incidence of clear cell renal cell carcinoma (ccRCC) is globally high; however, despite the introduction of innovative drug therapies, there remains a lack of effective biomarkers for evaluating treatment response. Recently, Caspase recruiting domain-containing protein 11 (CARD11) has garnered attention due to its significant association with tumor development and the immune system. Methods: The expression of CARD11 mRNA and protein in ccRCC were analyzed by public database and immunohistochemistry. The focus of this study is on the epigenomic modifications of CARD11, its expression of ccRCC immunophenotype, and its correlation with response to immunotherapy… More > Graphic Abstract

YANG XU^1,#, HONGYUN LI^1,#, GE YOU^2,*

BIOCELL, Vol.48, No.2, pp. 229-237, 2024, DOI:10.32604/biocell.2023.045030 - 23 February 2024

Abstract Background: Colorectal cancer (CRC) constitutes the leading cause of death worldwide. Chemoresistance and tumor immune evasion are critical contributors to therapeutic failure in cancer patients. CKLF-like MARVEL transmembrane domain-containing 6 (CMTM6) is aberrantly expressed in various cancers and can regulate tumor immunity. However, its role in chemoresistance and tumor immunity of CRC is not well understood. Methods: Online bioinformatics tools were used to analyze expression and prognosis of CMTM6 in CRC patients. CRC cells were transfected with si-CMTM6. Subsequently, the effects on CRC cell viability and chemoresistance were investigated by CCK-8 assay and flow cytometer.… More > Graphic Abstract

Zhou Ji¹, Mengmeng Zhou², Qiang Wang², Jiandong Huang^3,*

CMES-Computer Modeling in Engineering & Sciences, Vol.139, No.2, pp. 1557-1582, 2024, DOI:10.32604/cmes.2023.046025 - 29 January 2024

Abstract To improve the prediction accuracy of the International Roughness Index (IRI) of Jointed Plain Concrete Pavements (JPCP) and Continuously Reinforced Concrete Pavements (CRCP), a machine learning approach is developed in this study for the modelling, combining an improved Beetle Antennae Search (MBAS) algorithm and Random Forest (RF) model. The 10-fold cross-validation was applied to verify the reliability and accuracy of the model proposed in this study. The importance scores of all input variables on the IRI of JPCP and CRCP were analysed as well. The results by the comparative analysis showed the prediction accuracy of… More > Graphic Abstract

ZHIWANG LI, HAN YU, YUPING LIU, WEISHENG WU, HAIJING ZENG, EN LI^*

BIOCELL, Vol.47, No.11, pp. 2409-2422, 2023, DOI:10.32604/biocell.2023.031186 - 27 November 2023

Abstract Familial adenomatous polyposis (FAP) is an autosomal dominant disease with a high probability of becoming cancerous. Many RNAs potentially associated with FAP have not been identified. In this study, a circRNA (circular RNA) expression profile of FAP was established using a circRNA microarray, and differentially expressed circRNAs were verified by RT-qPCR. The effects of hsa_circ_0036740 on the malignant behavior of tumor cells (proliferation, apoptosis, and epithelial mesenchymal transition) and the levels of C3A complement protein expression were evaluated. Moreover, neutrophils were isolated and co-cultured with colorectal cancer cells (CRCs), followed by measurements of MPO-DNA, citrullinated… More > Graphic Abstract

YAN ZHUANG^1,#, CHUNLAN NING^2,3,#, PENGFEI LIU^4,#, YANPENG ZHAO⁵, YUE LI⁶, ZHENCHI MA⁶, LULING SHAN⁶, YINGZHE PIAO⁷, PENG ZHAO^6,*, XUN JIN^2,*

Oncology Research, Vol.30, No.6, pp. 289-300, 2022, DOI:10.32604/or.2022.028225 - 09 February 2023

Abstract Aberrant activation of the WNT signaling pathway is a joint event in colorectal cancer (CRC), but the molecular mechanism is still unclear. Recently, RNA-splicing factor LSM12 (like-Sm protein 12) is highly expressed in CRC tissues. This study aimed to verify whether LSM12 is involved in regulating CRC progression via regulating the WNT signaling pathway. Here, we found that LSM12 is highly expressed in CRC patient-derived tissues and cells. LSM12 is involved in the proliferation, invasion, and apoptosis of CRC cells, similar to the function of WNT signaling in CRC. Furthermore, protein interaction simulation and biochemical More >

Dayu Tian¹, Yang Shi¹, Li Lei¹, Xiangmin Qiu¹, Tao Song^2,*, Qianyin Li^1,*

Oncologie, Vol.24, No.2, pp. 261-282, 2022, DOI:10.32604/oncologie.2022.022838 - 29 June 2022

Abstract Background: Six2, a transcription factor, exerts an oncogenic role in clear cell renal cell carcinoma (ccRCC). Increased Six2 expression could enhance cancer metastasis. However, the regulatory mechanism of Six2 in promoting metastasis remains unclear. The purpose of this study is to analyze the regulatory pattern of Six2 and the potential role of Six2 in the tumor immune microenvironment. Materials and Methods: Firstly, transcriptional data in TCGA-KIRC cohorts was used to analyze the relationship between Six2 expression and clinical information. Secondly, we detect the association between Six2 and the tumor immune microenvironment in ccRCC. Then, we analyzed Six2-related… More >

Hsiang-Lin Tsai^*†, Yen-Cheng Chen^*‡, Tzu-Chieh Yin^*§¶, Wei-Chih Su^*‡, Po-Jung Chen^*,Tsung-Kun Chang^*†, Ching-Chun Li^*, Ching-Wen Huang^*†, Jaw-Yuan Wang^{*†‡#**††‡‡}

Oncology Research, Vol.29, No.1, pp. 47-61, 2021, DOI:10.3727/096504022X16451187313084

Abstract Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism plays a crucial role in the increased susceptibility and toxicity of patients to irinotecan. This retrospective, observational study compared the clinical outcomes and adverse events (AEs) in RAS wild-type metastatic colorectal cancer (mCRC) patients treated with cetuximab or bevacizumab plus FOLFIRI with UGT1A1 genotyping and irinotecan dose escalation as the first-line therapy. In total, 173 patients with mCRC with RAS wild-type were enrolled. Among them, 98 patients were treated with cetuximab, whereas 75 patients were treated with bevacizumab. All patients received irinotecan dose escalation based on UGT1A1 genotyping. We compared the progression-free… More >

Shuai Liu^*†1, Lu Lu^*†1, Feng Pan^‡, Chunsheng Yang^*†, Jing Liang^§, Jinfeng Liu^¶, Jian Wang^#, Rong Shen^**, Fu-Ze Xin^††, Nan Zhang^*†

Oncology Research, Vol.29, No.1, pp. 25-31, 2021, DOI:10.3727/096504022X16427607626672

Abstract Fruquintinib, also called HMPL-013, was first discovered by Hutchison Whampoa Pharmaceuticals Co. Ltd., Shanghai, China, and it is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. In clinical trials, fruquintinib has demonstrated a survival benefit in metastatic colorectal cancer (mCRC) patients. The purpose of this study was to retrospectively evaluate the efficacy and toxicity of fruquintinib in real-world patients. We collected data from patients with mCRC treated with oral fruquintinib from 2018 to 2020 in six different institutions. Patients with mCRC initially received 5 mg of oral fruquintinib daily for 3 weeks. Progression-free survival… More >